Martha M. Kirstein

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al. · Nature · 2021 · 1.2K citations · Full text

Life Sciences, Immunology, Oncology +17

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score

Bernhard Scheiner, Katharina Pomej, Martha M. Kirstein et al. · Journal of Hepatology · 2021 · 300 citations · Full text

Pharmacy, Immunology, Oncology +17

Epidemiology and Risk Factors of Cholangiocarcinoma

Martha M. Kirstein, Arndt Vogel · Visceral Medicine · 2016 · 185 citations · Full text

Medicine, Oncology, Pathology +14

Prediction of short‐ and long‐term outcome in patients with autoimmune hepatitis

Martha M. Kirstein, Frauke Metzler, Elena Geiger et al. · Hepatology · 2015 · 144 citations

Medicine, Immunology, Pathology +17

Programmed cell death protein‐1 (<scp>PD</scp>‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort

Bernhard Scheiner, Martha M. Kirstein, Florian Hucke et al. · Alimentary Pharmacology & Therapeutics · 2019 · 131 citations · Full text

Medicine, Immunology, Oncology +17